calcium acetate (Rx)

Brand and Other Names:Eliphos, PhosLo, more...Phoslyra, Calphron
  • Print

Dosing & Uses

AdultPediatricGeriatric

Dosage Forms & Strengths

capsule/tablet

  • 667mg (169mg elemental Ca)

oral solution

  • 667mg/5mL (169mg/5mL elemental Ca)

Hyperphosphatemia in End Stage Renal Failure (On Dialysis)

Initial: 2 capsules (1334 mg) PO with each meal

Increase dose to bring serum phosphate value <6 mg/dL as long as hypercalcemia does not develop

Usual Dose: 3-4 capsules (2001-2868 mg) PO with each meal

Other Information

Do not give additional calcium supplements

Safety and efficacy not established

Hyperphosphatemia in end stage renal failure (on dialysis)

Initial: 2 capsules (1334 mg) PO with each meal

Increase dose to bring serum phosphate value <6 mg/dL as long as hypercalcemia does not develop

Usual dose: 3-4 capsules (2001-2868 mg) PO with each meal

Next:

Interactions

Interaction Checker

and calcium acetate

No Results

     activity indicator 
    No Interactions Found
    Interactions Found

    Contraindicated

      Serious - Use Alternative

        Significant - Monitor Closely

          Minor

            All Interactions Sort By:
             activity indicator 

            Contraindicated (1)

            • ceftriaxone

              ceftriaxone, calcium acetate. Other (see comment). Contraindicated. Comment: Do not use ANY calcium containing solutions (including Ringer or Harmann solutions) in combination with IV ceftriaxone; risk of potentially fatal particulate precipitation in lungs, kidneys. Separate administration by at least 48 hrs.

            Serious - Use Alternative (8)

            • baloxavir marboxil

              calcium acetate will decrease the level or effect of baloxavir marboxil by cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted.

            • demeclocycline

              calcium acetate, demeclocycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

            • doxycycline

              calcium acetate, doxycycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

            • eltrombopag

              calcium acetate decreases levels of eltrombopag by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated. Separate by at least 4 hours.

            • erdafitinib

              calcium acetate, erdafitinib. Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid coadministration during initial dosing adjustment period (ie, first 21 days). Increases in serum phosphate levels are a pharmacodynamic effect of FGFR inhibition. Serum phosphate binders may obscure decisions regarding initial dosage increase.

            • minocycline

              calcium acetate, minocycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

            • oxytetracycline

              calcium acetate, oxytetracycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

            • tetracycline

              calcium acetate, tetracycline. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Separate by 2 hours.

            Monitor Closely (54)

            • acebutolol

              calcium acetate decreases effects of acebutolol by unspecified interaction mechanism. Use Caution/Monitor.

            • alendronate

              calcium acetate decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • amantadine

              calcium acetate will increase the level or effect of amantadine by Other (see comment). Modify Therapy/Monitor Closely. Urine pH changes towards alkalinic conditions may lead to an accumulation of amantadine with a possible increase in adverse reactions. Monitor for adverse reactions of amantadine.

            • amlodipine

              calcium acetate decreases effects of amlodipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • atenolol

              calcium acetate decreases effects of atenolol by unspecified interaction mechanism. Use Caution/Monitor.

            • betaxolol

              calcium acetate decreases effects of betaxolol by unspecified interaction mechanism. Use Caution/Monitor.

            • bictegravir

              calcium acetate will decrease the level or effect of bictegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Bictegravir can be taken under fasting conditions 2 hr before antacids containing Al, Mg, or Ca. Routine administration of bictegravir simultaneously with, or 2 hr after, antacids containing Al, Mg, or Ca is not recommended.

            • bisoprolol

              calcium acetate decreases effects of bisoprolol by unspecified interaction mechanism. Use Caution/Monitor.

            • carvedilol

              calcium acetate decreases effects of carvedilol by unspecified interaction mechanism. Use Caution/Monitor.

            • celiprolol

              calcium acetate decreases effects of celiprolol by unspecified interaction mechanism. Use Caution/Monitor.

            • ciprofloxacin

              calcium acetate decreases effects of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Ciprofloxacin should be administered 2 hr before or 6 hr after calcium salts.

            • clevidipine

              calcium acetate decreases effects of clevidipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • deferiprone

              calcium acetate decreases levels of deferiprone by enhancing GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Deferiprone may bind polyvalent cations (eg, iron, aluminum, and zinc), separate administration by at least 4 hr between deferiprone and other medications (eg, antacids), or supplements containing these polyvalent cations.

            • delafloxacin

              calcium acetate will decrease the level or effect of delafloxacin by cation binding in GI tract. Modify Therapy/Monitor Closely. Oral delafloxacin form chelates with alkaline earth and transition metal cations. Administer oral delafloxacin at least 2 hr before or 6 hr after these agents.

            • digoxin

              calcium acetate increases effects of digoxin by pharmacodynamic synergism. Use Caution/Monitor.

            • diltiazem

              calcium acetate decreases effects of diltiazem by pharmacodynamic antagonism. Use Caution/Monitor.

            • dolutegravir

              calcium acetate will decrease the level or effect of dolutegravir by cation binding in GI tract. Modify Therapy/Monitor Closely. Administer dolutegravir 2 hr (dolutegravir or abacavir/dolutegravir/lamivudine) or 4 hr (dolutegravir/rilpivirine) before or 6 hr after taking medications containing polyvalent cations.

            • esmolol

              calcium acetate decreases effects of esmolol by unspecified interaction mechanism. Use Caution/Monitor.

            • estramustine

              calcium acetate decreases levels of estramustine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Patients should take estramustine with water at least 1h before or 2h after meals.

            • etidronate

              calcium acetate decreases levels of etidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • felodipine

              calcium acetate decreases effects of felodipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • fleroxacin

              calcium acetate, fleroxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • gemifloxacin

              calcium acetate, gemifloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • ibandronate

              calcium acetate decreases levels of ibandronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • isradipine

              calcium acetate decreases effects of isradipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • labetalol

              calcium acetate decreases effects of labetalol by unspecified interaction mechanism. Use Caution/Monitor.

            • levofloxacin

              calcium acetate, levofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • levothyroxine

              calcium acetate decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate administration by 4 hours.

            • metoprolol

              calcium acetate decreases effects of metoprolol by unspecified interaction mechanism. Use Caution/Monitor.

            • moxifloxacin

              calcium acetate, moxifloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • nadolol

              calcium acetate decreases effects of nadolol by unspecified interaction mechanism. Use Caution/Monitor.

            • nebivolol

              calcium acetate decreases effects of nebivolol by unspecified interaction mechanism. Use Caution/Monitor.

            • nicardipine

              calcium acetate decreases effects of nicardipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • nifedipine

              calcium acetate decreases effects of nifedipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • nisoldipine

              calcium acetate decreases effects of nisoldipine by pharmacodynamic antagonism. Use Caution/Monitor.

            • ofloxacin

              calcium acetate, ofloxacin. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.

            • omadacycline

              calcium acetate will decrease the level or effect of omadacycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

            • pamidronate

              calcium acetate decreases levels of pamidronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • penbutolol

              calcium acetate decreases effects of penbutolol by unspecified interaction mechanism. Use Caution/Monitor.

            • pindolol

              calcium acetate decreases effects of pindolol by unspecified interaction mechanism. Use Caution/Monitor.

            • propranolol

              calcium acetate decreases effects of propranolol by unspecified interaction mechanism. Use Caution/Monitor.

            • rilpivirine

              calcium acetate decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Coadministration of antacids with rilpivirine may cause significant decreases in rilpivirine plasma concentrations because of increased gastric pH. If antacids must be administered, they should given at least 2 hr before or at least 4 hr after rilpivirine.

            • risedronate

              calcium acetate decreases levels of risedronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • sarecycline

              calcium acetate will decrease the level or effect of sarecycline by inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products.

            • sodium sulfate/?magnesium sulfate/potassium chloride

              sodium sulfate/?magnesium sulfate/potassium chloride increases toxicity of calcium acetate by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

            • sodium sulfate/potassium sulfate/magnesium sulfate

              sodium sulfate/potassium sulfate/magnesium sulfate increases toxicity of calcium acetate by Other (see comment). Use Caution/Monitor. Comment: Coadministration with medications that cause fluid and electrolyte abnormalities may increase the risk of adverse events of seizure, arrhythmias, and renal impairment.

            • sotalol

              calcium acetate decreases effects of sotalol by unspecified interaction mechanism. Use Caution/Monitor.

            • squill

              calcium acetate increases toxicity of squill by unspecified interaction mechanism. Use Caution/Monitor.

            • strontium ranelate

              calcium acetate decreases levels of strontium ranelate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Applies to oral form of calcium. Separate by 2 hr.

            • tiludronate

              calcium acetate decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            • timolol

              calcium acetate decreases effects of timolol by unspecified interaction mechanism. Use Caution/Monitor.

            • verapamil

              calcium acetate decreases effects of verapamil by pharmacodynamic antagonism. Use Caution/Monitor.

            • vitamin D

              vitamin D, calcium acetate. Other (see comment). Use Caution/Monitor. Comment: The concurrent use of vitamin D with calcium salts is generally beneficial; in some patients this combination may result in hypercalcemia.

            • zoledronic acid

              calcium acetate decreases levels of zoledronic acid by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 30 minutes.

            Minor (50)

            • amikacin

              amikacin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • amiloride

              amiloride decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • bendroflumethiazide

              bendroflumethiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • budesonide

              budesonide decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • bumetanide

              bumetanide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • caffeine

              caffeine decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • calcitriol topical

              calcitriol topical increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown. Topical calcitriol may lead to hypercalcemia.

            • carbonyl iron

              calcium acetate decreases levels of carbonyl iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              carbonyl iron increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • chlorothiazide

              chlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • chlorthalidone

              chlorthalidone increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • cortisone

              cortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • cyclopenthiazide

              cyclopenthiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • deflazacort

              deflazacort decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • dexamethasone

              dexamethasone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • drospirenone

              drospirenone decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • ethacrynic acid

              ethacrynic acid decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • ferric maltol

              ferric maltol increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              calcium acetate decreases levels of ferric maltol by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • ferrous fumarate

              calcium acetate decreases levels of ferrous fumarate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              ferrous fumarate increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • ferrous gluconate

              ferrous gluconate increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              calcium acetate decreases levels of ferrous gluconate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • ferrous sulfate

              ferrous sulfate increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • fludrocortisone

              fludrocortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • furosemide

              furosemide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • gentamicin

              gentamicin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • hydrochlorothiazide

              hydrochlorothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • hydrocortisone

              hydrocortisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • indapamide

              indapamide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • iron dextran complex

              calcium acetate decreases levels of iron dextran complex by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              iron dextran complex increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • iron sucrose

              calcium acetate decreases levels of iron sucrose by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              iron sucrose increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • isoniazid

              isoniazid decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • isotretinoin

              isotretinoin increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • lily of the valley

              calcium acetate increases effects of lily of the valley by unspecified interaction mechanism. Minor/Significance Unknown.

            • manganese

              calcium acetate, manganese. Either decreases levels of the other by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown. Separate by 2 hours.

            • methyclothiazide

              methyclothiazide increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • methylprednisolone

              methylprednisolone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • metolazone

              metolazone increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis, hypercalcemia.

            • neomycin PO

              neomycin PO decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • paromomycin

              paromomycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • polysaccharide iron

              calcium acetate decreases levels of polysaccharide iron by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              polysaccharide iron increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • prednisolone

              prednisolone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • prednisone

              prednisone decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • rose hips

              calcium acetate decreases levels of rose hips by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

              rose hips increases levels of calcium acetate by enhancing GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • shark cartilage

              calcium acetate, shark cartilage. pharmacodynamic synergism. Minor/Significance Unknown. May lead to hypercalcemia (theoretical).

            • sodium polystyrene sulfonate

              sodium polystyrene sulfonate increases levels of calcium acetate by decreasing renal clearance. Minor/Significance Unknown. Risk of alkalosis.

            • spironolactone

              spironolactone decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • streptomycin

              streptomycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • teriparatide

              teriparatide increases levels of calcium acetate by pharmacodynamic synergism. Minor/Significance Unknown.

            • tobramycin

              tobramycin decreases levels of calcium acetate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.

            • torsemide

              torsemide decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            • triamcinolone acetonide injectable suspension

              triamcinolone acetonide injectable suspension decreases levels of calcium acetate by increasing elimination. Minor/Significance Unknown.

            • triamterene

              triamterene decreases levels of calcium acetate by increasing renal clearance. Minor/Significance Unknown.

            Previous
            Next:

            Adverse Effects

            Frequency Not Defined

            Arrhythmias

            Hypomagnesemia

            Hypophosphatemia

            Hypotension

            Nausea

            Pruritus (rare)

            Weakness

            Hypercalcemia

            • Anorexia
            • Coma
            • Confusion
            • Delirium
            • Headache
            • Nausea
            • Vomiting
            Previous
            Next:

            Warnings

            Contraindications

            Hypersensitivity, hypercalcemia, renal calculi

            Cautions

            Constipation may occur

            Cardiac glycosides; hypercalcemia may aggravate digitalis toxicity

            Advise patients to limit intake of oxalate-rich foods (soy, green leafy vegetables, animal protein) to avoid Ca-Oxalate formation

            Patients with end-stage renal disease may develop hypercalcemia when treated with calcium; avoid concurrent use of calcium supplements, including calcium-based nonprescription antacids

            Early in the treatment phase during dosage adjustment period, monitor

            serum calcium levels twice weekly; should hypercalcemia develop, reduce dosage or discontinue treatment, depending on severity of hypercalcemia

            Severe hypercalcemia (Ca >12 mg/dL) associated with confusion, delirium, stupor, and coma; severe hypercalcemia can be treated by acute hemodialysis and discontinuing therapy

            Mild hypercalcemia (10.5 to 11.9 mg/dL) may be asymptomatic or manifest as constipation, anorexia, nausea, and vomiting; mild hypercalcemia is usually controlled by reducing dose or temporarily discontinuing therapy; decreasing or discontinuing Vitamin D therapy is recommended as well

            Chronic hypercalcemia may lead to vascular calcification and other soft-tissue calcification; radiographic evaluation of suspected anatomical regions may be helpful in early detection of soft tissue calcification; the long-term effect on progression of vascular or soft tissue calcification has not been determined

            Oral solution contains maltitol (1g/5mL) and may induce laxative effect if taken with other products containing maltitol

            Previous
            Next:

            Pregnancy & Lactation

            Pregnancy Category: C

            Maintenance of normal serum calcium levels is important for maternal and fetal well being; hypercalcemia during pregnancy may increase risk for maternal and neonatal complications(eg, stillbirth, preterm delivery, neonatal hypocalcemia and hypoparathyroidism);calcium acetate treatment, as recommended, is not expected to harm a fetus if maternal calcium levels are properly monitored during and following treatment

            Lactation: unknown

            Pregnancy Categories

            A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

            B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

            C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

            D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

            X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

            NA: Information not available.

            Previous
            Next:

            Pharmacology

            Mechanism of Action

            Chelates phosphate (& other anions, eg, oxalate) in intestine to form insoluble calcium phosphate, which is excreted in feces.

            Pharmacokinetics

            Absorption: 30-40%; however it is the unabsorbed drug that binds and removes phosphate

            Excretion: Feces and urine (20%)

            Previous
            Next:

            Images

            BRAND FORM. UNIT PRICE PILL IMAGE
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg tablet
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg tablet
            calcium acetate(phosphate binders) oral
            -
            667 mg tablet
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            calcium acetate(phosphate binders) oral
            -
            667 mg capsule
            Phoslyra oral
            -
            667 mg (169 mg calcium)/5 mL solution

            Copyright © 2010 First DataBank, Inc.

            Previous
            Next:

            Patient Handout

            Patient Education
            calcium acetate(phosphate binders) oral

            CALCIUM ACETATE - ORAL

            (KAL-see-um AS-e-tate)

            COMMON BRAND NAME(S): Phoslyra, PhosLo

            USES: Calcium acetate is used to prevent high blood phosphate levels in patients who are on dialysis due to severe kidney disease. Dialysis removes some phosphate from your blood, but it is difficult to remove enough to keep your phosphate levels balanced. Decreasing blood phosphate levels can help keep your bones strong, prevent unsafe buildup of minerals in your body, and possibly decrease the risk of heart disease and strokes that can result from high phosphate levels. Calcium acetate is a natural mineral that works by holding onto phosphate from the diet so that it can pass out of your body.

            HOW TO USE: If you are taking the over-the-counter product to self-treat, read and follow all directions on the product package before taking this medication. If you have any questions, consult your pharmacist. If your doctor has prescribed this medication, take it as directed.This medication is usually taken by mouth with each meal. The dosage is based on your medical condition and response to treatment.If you are using the liquid form, use a medication-measuring device or spoon to carefully measure the prescribed dose. Do not use a household spoon because you may not get the correct dose.Use this medication regularly in order to get the most benefit from it. Remember to take it with each meal every day or on the schedule given to you by your doctor.Take this medication exactly as directed. Do not increase your dose or take this more often than prescribed. Doing so may increase your risk of side effects.

            SIDE EFFECTS: Stomach upset may occur. If this effect persists or worsens, notify your doctor or pharmacist promptly.If your doctor has directed you to use this medication, remember that your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if any of these unlikely but serious side effects occur: stomach/abdominal pain, loss of appetite, nausea, vomiting, constipation, confusion, dry mouth, increased thirst/urination.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.

            PRECAUTIONS: Before taking calcium acetate, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.This medication should not be used if you have a certain medical condition. Before using this medicine, consult your doctor or pharmacist if you have: a high blood calcium level (hypercalcemia).Before using this medication, tell your doctor or pharmacist your medical history.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This medication passes into breast milk but is unlikely to harm a nursing infant. Consult your doctor before breast-feeding.

            DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: calcium channel blockers (e.g., verapamil), calcium supplements, antacids that contain calcium, iron supplements.This product can decrease the absorption of other drugs such as bisphosphonates (for example, alendronate), phenytoin, quinolone antibiotics (for example, ciprofloxacin, levofloxacin), strontium, thyroid medications (for example, levothyroxine), and tetracycline antibiotics (for example, doxycycline, minocycline). Separate your doses of these medications as far as possible from your doses of this product. Ask your doctor or pharmacist about how long you should wait between doses and for help finding a dosing schedule that will work with all your medications.

            OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include nausea, vomiting, loss of appetite, confusion, loss of consciousness.

            NOTES: Your doctor may direct you to follow a special diet to help lower your blood phosphate levels. Follow the diet closely.Laboratory and/or medical tests (e.g., blood phosphate and calcium levels) should be performed regularly to monitor your progress or check for side effects. Consult your doctor for more details.

            MISSED DOSE: If you miss a dose, take it as soon as you remember if you have just eaten. If you have not recently eaten or if it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.

            STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medicines away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.

            Information last revised August 2021. Copyright(c) 2021 First Databank, Inc.

            IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.

            Previous
            Next:

            Formulary

            FormularyPatient Discounts

            Adding plans allows you to compare formulary status to other drugs in the same class.

            To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

            Adding plans allows you to:

            • View the formulary and any restrictions for each plan.
            • Manage and view all your plans together – even plans in different states.
            • Compare formulary status to other drugs in the same class.
            • Access your plan list on any device – mobile or desktop.

            The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

            Tier Description
            1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
            2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
            3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
            4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
            NC NOT COVERED – Drugs that are not covered by the plan.
            Code Definition
            PA Prior Authorization
            Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
            QL Quantity Limits
            Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
            ST Step Therapy
            Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
            OR Other Restrictions
            Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
            Additional Offers
            Email to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Email Forms to Patient

            From:

            To:

            The recipient will receive more details and instructions to access this offer.

            By clicking send, you acknowledge that you have permission to email the recipient with this information.

            Previous
            Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.